J&J appoints Executive Vice President of Pharmaceuticals, R&D
Johnson & Johnson has appointed John Reed, M.D., Ph.D., to the company’s executive committee as Executive Vice President of Pharmaceuticals, R&D.
Dr. Reed will join Johnson & Johnson on April 3, 2023, assuming responsibility for the company’s portfolio from William Hait, M.D., Ph.D., who has served as interim head of Johnson & Johnson’s Pharmaceutical R&D organization since August 2022.
Dr. Reed joins J&J from Sanofi - where he was the company’s R&D head for four years - and brings with him 35 years of biomedical research leadership.
Prior to Sanofi, Dr. Reed served as Global Head of Pharmaceutical Research & Early Development at Roche, where he was also a member of the company’s Executive Committee, and CEO of a large, independent, non-profit biomedical research institute in La Jolla, California.
Dr. Reed has authored more than 900 research publications and invented over 130 patents. He was recognized among the top 10 most cited researchers in life sciences and medicine for a decade and still ranks among the world’s top 100 most highly cited scientists.
Dr. Reed is a graduate of the University of Pennsylvania School of Medicine. He trained in Molecular Biology at the Wistar Institute and in Clinical Pathology & Laboratory Medicine at the Hospital of the University of Pennsylvania. He is a Fellow of the American Association for the Advancement of Science and the recipient of numerous honors and awards.
Sanofi is conducting an internal and external search for its next R&D head. In the meantime, Dr. Dietmar Berger has agreed to take the leadership of the team ad interim. Dr. Berger has been serving as Chief Medical Officer and Global Head of Development since he joined Sanofi in 2019, after an extensive and successful career at various other pharmaceutical companies including Genentech, Bayer and Amgen.
